Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Johnson & Johnson q2 2019 earnings

Johnson & Johnson q2 2019 earnings

Johnson & Johnson's earnings jumped 42 percent in the second quarter, with all three healthcare businesses performing better than expected on Wall Street.

  • Revenue per share: $ 2.58, adjusted to $ 2.46 expected
  • Revenues: $ 20.56 billion compared to the $ 20.29 billion expected
  • ] The company reported a net profit for the second quarter of $ 5.61 billion, or $ 2.08 per share, a 42% increase of $ 3.95 billion, or $ 1.45 per share, reported it year on -arranged. Excluding intangible amortization and special items, J & J earned $ 2.58 per share, defeating $ 2.46 per share expected by analysts interviewed by Refinitiv. , but still exceed analysts' expectations of $ 20.29 billion. J & J's pharmaceutical business, which accounts for half of the company's revenue and includes psoriasis medications like Stelara and Tremfya, reported revenue of $ 3.54 billion, better than expected analysts at $ 3.52 billion, according to StreetAccount estimates. making Aveeno's body and J & J baby products, reported $ 3.54 billion in revenue, surpassing the estimated $ 3.52 billion in analysts. His medical device business, which includes Acuvue contacts and Ethicon surgical products, reported revenues of 6.49 billion dollars. Analysts expected $ 6.43 billion.

    "We have achieved a solid second quarter in the base of sales growth and strong revenue growth, enabling us to invest in innovation to accelerate performance in each of our businesses," said J & J Alex CEO Forest. Sales forecasts are between $ 80.8 billion and $ 81

    .6 billion, compared to the previous $ 80.4 billion to $ 81.2 billion. The company has not raised its profit forecast by repeating its previous forecast for adjusted earnings ranging from $ 8.53 to $ 8.63 per share

    J & J shares rose 0.4% in pre-emptive trading. sales of some of his best drugs, such as Zytiga, while introducing new ones such as Spravato. The treatment of prostate cancer Zytiga lost patent protection last fall and now faces competition from a handful of generic medicines. Meanwhile, J & J won the approval of the US Food and Drug Administration in the spring for Spravato as a ketamine-like spray for the treatment of depressive-resistant treatment.

    Mesothelioma threatening the family image of the company. The company has fought the charges and insists that her baby is safe.

Source link